NCT00661245Unknown3 期
Transoral Gastroplasty for the Treatment of Morbid Obesity
Satiety, Inc.20 个研究点 分布在 2 个国家目标入组 275 人开始时间: 2008年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 275
- 试验地点
- 20
- 主要终点
- Effectiveness: The proportion of subjects with ≥ 25% EWL (excess weight loss); Safety: Pre-defined objective performance criteria (OPC)
研究概览
简要总结
The TOGA® trial is a prospective, multi-center, randomized sham-controlled trial designed to determine the safety and effectiveness of the TOGA System for the treatment of morbid obesity. The study will also determine the effect of the treatment on co-morbidities and quality of life.
Subjects will be blinded to treatment or sham. Sham arm may crossover to TOGA treatment at 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •BMI ≥ 40 kg/m2 and < 55 kg/m2, or BMI ≥ 35 kg/m2 with one or more significant co morbidities
- •History of obesity for at least 2.5 years.
- •History of stable weight (defined as a < 10% change in excess weight) for one year prior to the screening visit.
- •History of failure with non-surgical weight loss methods.
- •Suitable candidate for bariatric surgery based on the results of their psychological and physical evaluations.
- •Understands risks of procedure, agrees to follow protocol requirements, including signing informed consent, returning for follow-up visits, completing all required testing, completing diet and behavior modification counseling, committing to prolonged lifestyle changes, and agrees to comply with the substantial dietary restrictions required by the procedure.
- •Subject lives, and intends to remain, within a 100 mile radius of the study center for 5 years.
排除标准
- •Hormonal or genetic cause for the obese state.
- •History of cancer other than localized basal cell carcinoma.
- •History of inflammatory disease of the gastrointestinal tract including Crohn's disease, ulcerative colitis, severe intractable esophagitis, gastric ulceration, or esophageal or duodenal ulceration.
- •Active peptic ulcer disease.
- •Significant known esophageal disease, including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, diffuse esophageal spasm, and symptoms of dysmotility.
- •Myocardial infarction or cerebrovascular accident within past year.
- •Angina pectoris.
- •Inability to extend neck or fully open mouth.
- •Clinically severe cervical spinal disease, including cervical disc disease, vertebral osteophytes.
- •Critically loose teeth.
- •Temporomandibular joint syndrome (TMJ) or patients at risk for developing TMJ.
- •Severe coagulopathy (prothrombin time > 3 seconds over control or platelet count < 100,000)
- •Gastroparesis
- •Upper GI bleeding conditions such as esophageal or gastric varices, portal hypertensive gastropathy, congenital or acquired intestinal telangiectasis.
- •Congenital or acquired anomalies of the GI tract such as atresias or stenoses.
- •Structural abnormalities of the GI tract such as diverticulum.
- •Lesions with increased risk of bleeding.
- •Hiatal hernia ≥ 2cm.
- •Severe cardiopulmonary disease or other serious organic disease, including HIV or cancer.
- •Congestive heart failure.
- •Uncontrolled hypertension (systolic >150 or diastolic > 100).
- •Advanced rheumatoid arthritis.
- •Severe or advanced liver disease (such as cirrhosis, chronic hepatitis, portal hypertension, etc.).
- •Chronic pancreatitis.
- •Any contraindication to endoscopy.
- •Severe reflux disease.
- •Currently pregnant or nursing.
- •Potentially childbearing (i.e. not post-menopausal or surgically sterilized) and not willing to use an effective method of contraception for the next 24 months.
- •Alcohol (> 80 gm/day of ethanol) or illicit drug use within the last 3 years.
- •Prior gastric, esophageal, pancreatic or bariatric surgery.
- •Currently on prescription or over the counter diet drugs.
- •Chronic therapy with aspirin, NSAID or anticoagulants.
- •Systemic infection at the time of the procedure.
- •Patient with a known diagnosis or pre-existing symptoms of autoimmune connective tissue disease (i.e., systemic lupus erythematosus or scleroderma).
- •Thyroid disease which is not controlled with medication
- •Unacceptable medical risk (general health status would preclude surgery should a complication occur).
- •Not ambulatory.
- •Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of the clinical trial.
结局指标
主要结局
Effectiveness: The proportion of subjects with ≥ 25% EWL (excess weight loss); Safety: Pre-defined objective performance criteria (OPC)
时间窗: 12 months
次要结局
- Improvement in Co-morbidities; Improvements in other Obesity Measures and in Quality of Life Measures(12 months)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
1 期
Transoral Gastric Volume Reduction as an Intervention for Weight ManagementObesityNCT00679848C. R. Bard18
终止
2 期
Gastrografin for Treating Small Bowel Obstruction in ChildrenSmall Bowel ObstructionNCT03573921Lawson Health Research Institute2
撤回
不适用
A Trial to Evaluate Natural Orifice Transgastric Endoscopic Cholecystectomy With Laparoscopic AssistanceCholecystectomyNCT00979186Ethicon Endo-Surgery
进行中（未招募）
2 期
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal CancerHuman Papilloma Virus InfectionStage III Squamous Cell Carcinoma of the OropharynxStage IVA Squamous Cell Carcinoma of the OropharynxStage IVB Squamous Cell Carcinoma of the OropharynxNCT01898494ECOG-ACRIN Cancer Research Group519
撤回
不适用
Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic TreatmentOrthodontic MalocclusionNCT01866345University of Minnesota